glp 1 agonist inflammation The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs—Therapeutic potential exploration in lung injury Advances in GLP-1 receptor agonists

doi: 10.1016/j.jacc.2024.02.009 75 EcheverraLERojasLZSerrano-GarcaAYBoteroDRCantillo-ReinesMJuradoAMet al

3b,c), the increase of [Ca 2+ ] i measured at the end-point was instead explained by TRPA1 channel activation in response to JWU-A021

While their glycemic, weight-lowering, and cardiovascular benefits are well established through randomized trials and meta-analyses, concerns remain regarding their safety and tolerability across diverse populations and clinical settings

DPP-4 inhibitors: Generally discontinued when starting GLP-1 since both affect the incretin system

That's the company that makes Ozempic and Wegovy

Disclosures Disclosure forms, as provided by each author, are available with the online version of the article at Funding None